Advances in Ocular Drug Delivery

REFERENCES

• Diagram of the Eye. [cited March 7, 2011]; Available from: http://www.vcu.edu/eye/FAQ.html.
   Google Scholar
• Seeley RR, Stephens TD, Tate P, editors. Anatomy and Physiology. 8 ed. New York, NY: McGraw Hill; 2008.
   Google Scholar
• Lawrence MS, Miller JW. Ocular tissue permeabilities. Int Ophthalmol Clin. 2004;44:53–61.
   PubMedGoogle Scholar
• Hillery AA, Lloyd AW, Swarbick J, editors. Drug Delivery and Targeting for Pharmacists and Pharmaceutical Scientists. New York, NY: Taylor and Francis Inc; 2001.
   Google Scholar
• Allen LV, Popovich NG, Ansel HC, editors. Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. 8 ed. Baltimore, MD: Lippincott Williams and Wilkins; 2005.
   Google Scholar
• Lang JC, Roehrs RE, Rodeheaver DP, Missel PJ, Jani R, Chowhan MA. Design and Evaluation of Ophthalmic Pharmaceutical Products. In: Banker GS, Rhodes CT, editors. Modern Pharmaceutics. 4 ed. New York, NY: Marcel Dekker, Inc.; 2002. pp 415–478.
   Google Scholar
• Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12:348–360.
   PubMed Web of Science ®Google Scholar
• Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26:1197–1216.
   PubMed Web of Science ®Google Scholar
• Majumdar S, Hingorani T, Srirangam R, Gadepalli RS, Rimoldi JM, Repka MA. Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement. Pharm Res. 2009;26:1261–1269.
   PubMed Web of Science ®Google Scholar
• Karla PK, Pal D, Quinn T, Mitra AK. Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux. Int J Pharm. 2007;336:12–21.
   PubMed Web of Science ®Google Scholar
• Hariharan S, Gunda S, Mishra GP, Pal D, Mitra AK. Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res. 2009;26:1270–1282.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 2002;28:473–493.
   PubMed Web of Science ®Google Scholar
• Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21:15–34.
   PubMed Web of Science ®Google Scholar
• VeriDoser Ophthalmic Delivery System. Mystic pharmaceuticals; [2009; cited October 27, 2010]; Available from: http://www.mysticpharmaceuticals.com/DrugDeliveryTechnology/OphthalmicDelivery.htm.
   Google Scholar
• Veridoser delivery platform. [cited November 8, 2010]; Available from: http://www.mysticpharmaceuticals.com/DrugDeliveryTechnology/DeliveryPlatforms.htm.
   Google Scholar
• Budai L, Hajdú M, Budai M et al. Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. Int J Pharm. 2007;343:34–40.
   PubMed Web of Science ®Google Scholar
• Hosny KM. Optimization of gatifloxacin liposomal hydrogel for enhanced transcorneal permeation. J Liposome Res. 2010;20:31–37.
   PubMed Web of Science ®Google Scholar
• Li N, Zhuang C, Wang M, Sun X, Nie S, Pan W. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm. 2009;379:131–138.
   PubMed Web of Science ®Google Scholar
• Fialho SL, da Silva-Cunha A. New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Experiment Ophthalmol. 2004;32:626–632.
   PubMed Web of Science ®Google Scholar
• Peng CC, Bengani LC, Jung HJ, Leclerc J, Gupta C, and Chuahan A. Emulsions and microemulsions for ocular drug delivery. J Drug Deliv Sci Tech. 2011;21:111–121.
   Web of Science ®Google Scholar
• Chan J, Maghraby GM, Craig JP, Alany RG. Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. Int J Pharm. 2007;328:65–71.
   PubMed Web of Science ®Google Scholar
• Kapoor Y, Chauhan A. Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels. Int J Pharm. 2008;361:222–229.
   PubMed Web of Science ®Google Scholar
• De TK, Rodman DJ, Holm BA, Prasad PN, Bergey EJ. Brimonidine formulation in polyacrylic acid nanoparticles for ophthalmic delivery. J Microencapsul. 2003;20:361–374.
   PubMed Web of Science ®Google Scholar
• Adibkia K, Siahi Shadbad MR, Nokhodchi A et al. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target. 2007;15:407–416.
   PubMed Web of Science ®Google Scholar
• Kasseem MA, Abdel AA, Ghorab MM, Ahmed MB and Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340:126–133.
   PubMedGoogle Scholar
• Products & Technologies–LX214. Lux Biosciences, Inc; [cited November 8, 2010]; Available from: www.luxbio.com/LX214.htm.
   Google Scholar
• Rathore KS, Nema RK. Review on ocular inserts. Int J PharmTech Res. 2009;1:164–169.
   Google Scholar
• Sahane NK, Banarjee SK, Gaikwad DD, Jadhav SL, Thorat RM. Ocular inserts: a review. DIT. 2010;2:57–64.
   Google Scholar
• Koffler BH, McDonald M, Nelinson DS; LAC-07-01 Study Group. Improved signs, symptoms, and quality of life associated with dry eye syndrome: hydroxypropyl cellulose ophthalmic insert patient registry. Eye Contact Lens. 2010;36:170–176.
   PubMed Web of Science ®Google Scholar
• Jain D, Carvalho E, Banerjee R. Biodegradable hybrid polymeric membranes for ocular drug delivery. Acta Biomater. 2010;6:1370–1379.
   PubMed Web of Science ®Google Scholar
• Weyenberg W, Vermeire A, Dhondt MM et al. Ocular bioerodible minitablets as strategy for the management of microbial keratitis. Invest Ophthalmol Vis Sci. 2004;45:3229–3233.
   PubMed Web of Science ®Google Scholar
• Pijls RT, Sonderkamp T, Daube GW et al. Studies on a new device for drug delivery to the eye. Eur J Pharm Biopharm. 2005;59:283–288.
   PubMed Web of Science ®Google Scholar
• Pijls RT, Cruysberg LP, Nuijts RM, Dias AA, Koole LH. Capacity and tolerance of a new device for ocular drug delivery. Int J Pharm. 2007;341:152–161.
   PubMed Web of Science ®Google Scholar
• Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010;27:2043–2053.
   PubMed Web of Science ®Google Scholar
• Conference call to discuss q2 2009 financial results and latanoprost punctal plug delivery system (L-PPDS). QLT Inc; 2009; cited October 20, 2010]; Available from: http://www.qltinc.com/documents/090728_QLT_Slides.pdf.
   Google Scholar
• QLT Inc. Conference call to discuss q22009 financial results and latanoprost punctal plug delivery system (L-PPDS). QLT Inc; 2009 [updated 2009; cited 2010 October 20 2010]; Available from: http://www.qltinc.com/documents/090728_QLT_Slides.pdf.
   Google Scholar
• Bacterial conunctivitis. Ocular Therapeutix, Inc.; [2010; cited October 27, 2010]; Available from: www.ocutx.com/pipeline/drugdelivery/applications/bacterialconjunctivitis.
   Google Scholar
• Mitra AK, editor. Ophthalmic drug delivery systems. 2 ed. New York, NY: Marcel Dekker; 2003.
   Google Scholar
• EyeGate pharma initiates alluvion phase iii study of egp-437 in patients with dry eye syndrome. Eyegate Pharmaceuticals, Inc; [2010; cited October 27, 2010]; Available from: http://eyegatepharma.com/pdf/news2010/EyegatePR_DES_Ph%20III_Final.pdf.
   Google Scholar
• Choonara YE, Pillay V, Danckwerts MP, Carmichael TR, du Toit LC. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. J Pharm Sci. 2010;99:2219–2239.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Ashton P, Pearson PA, editors. Intraocular drug delivery. New York, NY: Taylor and Francis; 2006.
   Google Scholar
• Therapeutic areas – retinal disorders. RXi Pharmaceuticals, Inc [2010; cited November 3, 2010]; Available from: www.rxipharma.com/therapeutic-areas/retinal-disorder.
   Google Scholar
• RXi Pharmaceuticals and EyeGate Pharma announce collaboration focused on non-invasive ocular delivery of RNAi Therapeutics. Business Wire; [September 22, 2010; cited October 27, 2010]; Available from: www.businesswire.com/news/home/20100922005477/en/RXi-Pharmaceuticals-EyeGate-Pharma-Announce-Collaboration-Focused
   Google Scholar
• RNAi Technology. RXi Pharmaceuticals, Inc; [2010; cited November 3, 2010]; Available from: http://rxipharma.com/technology.
   Google Scholar
• Eljarrat-Binstock E, Pe’er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res. 2010;27:530–543.
   PubMed Web of Science ®Google Scholar
• Products Overview - ILUVIEN® for DME. Alimera Sciences [2010; cited November 4, 2010]; Available from: http://www.alimerasciences.com/Products/iluvien.aspx.
   Google Scholar
• Iluvien. [cited March 7, 2011]; Available from: http://www.drugdevelopment-technology.com/projects/iluvienfordiabeticma/iluvienfordiabeticma4.html.
   Google Scholar
• Pearson PA. Flucinolone Insert’s Impact on Overall Risk of Procedures. Retina Today. 2010 October:72–74.
   Google Scholar
• Analysis from FAME study finds intravitreal insert effctive for treating DME at 30 months. OSN SuperSite; [2010; cited November 4, 2010]; Available from: www.osnsupersite.com/view.aspx?rid = 65057
   Google Scholar
• News & Events - FDA issues complete response letter regarding new drug application for ILUVIEN(R). pSivida Corp.; [Dec 23, 2010; cited January 14, 2011]; Available from: http://phx.corporate-ir.net/phoenix.zhtml?c = 168274&p=irol-newsArticle&ID = 1510654&highlight=.
   Google Scholar
• News - FDA Issues complete response letter to alimera sciences regarding new drug application for ILUVIEN(R). Alimera Sciences, Inc.; [Dec 23, 2011; cited January 14, 2011]; Available from: http://investor.alimerasciences.com/releasedetail.cfm?ReleaseID = 538819.
   Google Scholar
• About encapsulated cell technology. Neurotech; [2010; cited November 7, 2010]; Available from: www.neurotechusa.com/ect/about_cell_technology.asp.
   Google Scholar
• About encapsulated cell technology - NT-501. Neurotech; [2010; cited November 7, 2010]; Available from: www.neurotechusa.com/ect/nt-501.asp
   Google Scholar
• Ozurdex product. [cited March 7, 2011]; Available from: http://www.retinamaculainstitute.com/treatments/implants.
   Google Scholar
• Verisome – Technology Overview. Icon Bioscience, Inc.; [2009; cited November 7, 2010]; Available from: www.iconbioscience.com/Technology-Overview.html
   Google Scholar
• Pipeline – IBI-20089. Icon Bioscience, Inc.; [2009; cited November 7, 2010]; Available from: www.iconbioscience.com/IBI-20089.html
   Google Scholar
• Technologies – Photodynamic therapy (PDT). QLT Inc; [2009; cited October 20, 2010]; Available from: www.qltinc.com/development/technologies/pdt.htm.
   Google Scholar
• Berdugo M, Bejjani RA, Valamanesh F et al. Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes. Invest Ophthalmol Vis Sci. 2008;49:1633–1644.
   PubMed Web of Science ®Google Scholar
• Safety and preliminary study of WST11 (Stakel)-Mediated VTP Therapy in subjects with CNV associated with AMD. clinicaltrials.com; [June 1, 2010; cited November 8, 2010]; Available from: http://www.clinicaltrials.gov/ct2/show/NCT01021956?term=NCT01021956&rank = 1.
   Google Scholar